Last week, we wrote about good news regarding lung cancer medication. Now, we present good news about a new breast cancer drug.
From AstraZeneca & Merck: Good News About a New Breast Cancer Drug
A drug sold by AstraZeneca and Merck reduced the recurrence of breast cancer in women with an early but aggressive form of the disease. According to a long-running international study found. The finding, was published online by the New England Journal of Medicine. As well as released at a major cancer-research meeting. That marked the latest advance in cancer treatments targeting the genetic traits of tumors. It could expand the arsenal of weapons against a hereditary form of breast cancer. The result also helps validate the investment in a pricey new class of drugs that target cancer cells. Known as PARP inhibitors.
AstraZeneca’s pill, named Lynparza, quickly became one of the company’s top sellers. Generating $1.8 billion in sales last year. Lynparza carries a U.S. list price of about $14,449 per patient monthly. AstraZeneca plans to submit data to regulators and request regulatory approval of the use of Lynparza for early-stage BRCA breast cancer. Said David Fredrickson, executive vice president of AstraZeneca’s oncology unit.
PARP inhibitors work by blocking cancer cells from relying on a survival tactic. The ability to repair their own DNA after their DNA gets damaged naturally or by other drug treatments. This, in turn, contributes to cancer-cell death.
Click the image to access the study.